Mexico reports first human case of H5N1 bird flu
MEXICO CITY (Reuters) - Mexico has detected its first human case of H5N1 avian influenza, also known as bird flu, the health ministry said on Friday.
The infection was confirmed on Tuesday in a three-year-old girl living in the northern state of Durango, who remains hospitalized in serious condition.
"So far there is no evidence of sustained person-to-person transmission," the health ministry said in a statement, adding that the World Health Organization (WHO) considers the public health risks of the virus to the general population to be low.
A particularly severe variant of the H5N1 strain has been spreading around the world in animals since 2020, causing lethal outbreaks in commercial poultry and sporadic infections in other species from alpacas to house cats. Last year, it was detected in cows for the first time.
Durango's economy is heavily reliant on agriculture, primarily its cattle industry.
Last year, the WHO reported Mexico's first laboratory-confirmed human case of infection with the A(H5N2) bird flu in a person who had no known exposure to animals and later died of chronic illness.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients
Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL study. New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines Bensheim, Germany – 13th June 2025 – According to the World Health Organization, an estimated 56.8 million palliative care patients worldwide suffer from significant symptom burden every year. In palliative care — particularly for oncology patients — effective symptom management is essential to maintaining dignity, comfort, and quality of life in the final stages of illness. Despite advances in conventional therapies, many patients continue to suffer from uncontrolled pain, anxiety, and other distressing symptoms. The CORAL study offers promising evidence that cannabinoid-based medicines may play a critical role in addressing this unmet need. The CORAL study (CannabinOid-TheRapie in der PALliativmedizin or Cannabinoid Therapy in Palliative Care) is a non-interventional, parallel group study designed to examine the reduction of symptom burden in patients receiving end-of-life care. Led by Prof. Dr. med. Sven Gottschling from Universitätsklinikum des Saarlandes in Homburg, 150 patients in advanced palliative stages were enrolled in the study, with over 80% being oncology patients. 100 of them were additionally treated with the cannabis extract Avextra 10:10 (THC/CBD), the other 50 with a non-cannabinoid treatment. Key Findings from the CORAL Study Significant Symptom Reduction: Patients treated with Avextra's extract showed statistically and clinically significant improvement in MIDOS scores (a palliative symptom assessment tool), while the control group's symptoms worsened. 68% of patients treated with Avextra showed clinically relevant improvement (≥20%). Mental Health Improvements: Stress, anxiety, and depression levels (measured by DASS-21) improved in the Avextra group, but worsened in the control group. All were statistically and clinically superior to the control group ; 50% were stress responders, and over 20% improved in all three DASS categories. Quality of Life Gains: Patients reported better outcomes across multiple domains in the EORTC QLQ-C15-PAL questionnaire, a quality-of-life tool validated for palliative care. Nearly 25% of patients in the Avextra group showed clinically relevant quality of life improvement. Lower Co-medication Burden: Avextra-treated patients require significantly less use of sedatives, sleep aids, benzodiazepines, and muscle relaxants. High Tolerability: The extract was well tolerated, with fewer than 15% of patients reporting any adverse reactions and only three dropouts due to side effects. Principal investigator Prof. Dr. Sven Gottschling, Head Physician of the Center for All-Age Palliative Medicine and Paediatric Pain Therapy at the UKS in Homburg, presents the study results during the 6th Medicinal Cannabis Congress in Berlin. He stated: "The CORAL study is another significant contribution to improving the treatment of those with serious, terminal diseases. We would like to thank our study partner Avextra: Together, we are committed to improving symptom burden reduction of those affected and further optimizing palliative care treatment options for patients and caregivers." Enhanced quality of life towards the end of lifeThere is a significant need for interdisciplinary studies, particularly in palliative care. This was highlighted in February by representatives of the Leopoldina (German National Academy of Sciences) and other scientific experts in Berlin. "Avextra's goal is to further improve symptom relief for palliative care patients. We are happy that our products appear to be helping to achieve that, and this motivates us to develop even better, innovative dosage forms for this patient group," said Dr. Bernhard Babel, CEO of Avextra. About Avextra AG Avextra is one of Europe's leading vertically integrated medical cannabis operators focused on the development and production of regulator-approved medicines. Founded in 2019 and based in Germany, the company works in close collaboration with doctors, pharmacists and researchers to develop and produce innovative Cannabis-based Medicines. Avextra controls the entire value chain – from cultivation to EU-GMP certified extraction and manufacturing in Germany. Avextra´s products are distributed in federally regulated cannabis access programmes across Europe. Going forward, Avextra will keep conducting studies focusing on the clinical outcomes of cannabis-based medicines on patients' overall reduction of symptom burden. Clinical trials represent a key element of the German biotech company's strategic focus towards getting a registered medicine. Learn more at and stay up to date at LinkedIn: Avextra Media Enquiries: For media enquiries or to set up an interview please contact: Email: press@ Phone: +49 30 408174037 Attachment Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients
Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL study. New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines Bensheim, Germany – 13th June 2025 – According to the World Health Organization, an estimated 56.8 million palliative care patients worldwide suffer from significant symptom burden every year. In palliative care — particularly for oncology patients — effective symptom management is essential to maintaining dignity, comfort, and quality of life in the final stages of illness. Despite advances in conventional therapies, many patients continue to suffer from uncontrolled pain, anxiety, and other distressing symptoms. The CORAL study offers promising evidence that cannabinoid-based medicines may play a critical role in addressing this unmet need. The CORAL study (CannabinOid-TheRapie in der PALliativmedizin or Cannabinoid Therapy in Palliative Care) is a non-interventional, parallel group study designed to examine the reduction of symptom burden in patients receiving end-of-life care. Led by Prof. Dr. med. Sven Gottschling from Universitätsklinikum des Saarlandes in Homburg, 150 patients in advanced palliative stages were enrolled in the study, with over 80% being oncology patients. 100 of them were additionally treated with the cannabis extract Avextra 10:10 (THC/CBD), the other 50 with a non-cannabinoid treatment. Key Findings from the CORAL Study Significant Symptom Reduction: Patients treated with Avextra's extract showed statistically and clinically significant improvement in MIDOS scores (a palliative symptom assessment tool), while the control group's symptoms worsened. 68% of patients treated with Avextra showed clinically relevant improvement (≥20%). Mental Health Improvements: Stress, anxiety, and depression levels (measured by DASS-21) improved in the Avextra group, but worsened in the control group. All were statistically and clinically superior to the control group ; 50% were stress responders, and over 20% improved in all three DASS categories. Quality of Life Gains: Patients reported better outcomes across multiple domains in the EORTC QLQ-C15-PAL questionnaire, a quality-of-life tool validated for palliative care. Nearly 25% of patients in the Avextra group showed clinically relevant quality of life improvement. Lower Co-medication Burden: Avextra-treated patients require significantly less use of sedatives, sleep aids, benzodiazepines, and muscle relaxants. High Tolerability: The extract was well tolerated, with fewer than 15% of patients reporting any adverse reactions and only three dropouts due to side effects. Principal investigator Prof. Dr. Sven Gottschling, Head Physician of the Center for All-Age Palliative Medicine and Paediatric Pain Therapy at the UKS in Homburg, presents the study results during the 6th Medicinal Cannabis Congress in Berlin. He stated: "The CORAL study is another significant contribution to improving the treatment of those with serious, terminal diseases. We would like to thank our study partner Avextra: Together, we are committed to improving symptom burden reduction of those affected and further optimizing palliative care treatment options for patients and caregivers." Enhanced quality of life towards the end of lifeThere is a significant need for interdisciplinary studies, particularly in palliative care. This was highlighted in February by representatives of the Leopoldina (German National Academy of Sciences) and other scientific experts in Berlin. "Avextra's goal is to further improve symptom relief for palliative care patients. We are happy that our products appear to be helping to achieve that, and this motivates us to develop even better, innovative dosage forms for this patient group," said Dr. Bernhard Babel, CEO of Avextra. About Avextra AG Avextra is one of Europe's leading vertically integrated medical cannabis operators focused on the development and production of regulator-approved medicines. Founded in 2019 and based in Germany, the company works in close collaboration with doctors, pharmacists and researchers to develop and produce innovative Cannabis-based Medicines. Avextra controls the entire value chain – from cultivation to EU-GMP certified extraction and manufacturing in Germany. Avextra´s products are distributed in federally regulated cannabis access programmes across Europe. Going forward, Avextra will keep conducting studies focusing on the clinical outcomes of cannabis-based medicines on patients' overall reduction of symptom burden. Clinical trials represent a key element of the German biotech company's strategic focus towards getting a registered medicine. Learn more at and stay up to date at LinkedIn: Avextra Media Enquiries: For media enquiries or to set up an interview please contact: Email: press@ Phone: +49 30 408174037 Attachment Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hamilton Spectator
11 hours ago
- Hamilton Spectator
Premature baby dies with measles
As measles cases across Elgin County and North America continue to rise, a southwestern Ontario infant infected by its unimmunized mother was identified June 5 as Canada's first death related to a measles outbreak that took hold of the nation on Oct. 30, 2024. 'It is with deep sadness that I confirm that an infant, born prematurely and infected with measles, has tragically passed away in southwestern Ontario,' Dr. Kieran Moore, Ontario's Chief Medical Officer of Health said in a statement. Dr. Moore said the infant contracted the virus before birth from the unimmunized mother. While measles may have been a contributing factor in both the premature birth and death, Dr. Moore said that the infant also faced other serious medical complications unrelated to the virus. 'Anyone who is unvaccinated is at risk and I urge everyone, but especially those who may become pregnant, to ensure they have received two doses of the MMR (measles, mumps, and rubella) vaccine, which will protect both a parent and baby,' added Dr. Moore. 'This vaccine has been safely used for over 50 years and is highly effective.' Dr. Ninh Tran, Southwestern Public Health's Medical Officer of Health added: 'This event underscores the seriousness of measles in pregnant individuals, as it can cause low birth weight for the baby, preterm birth, and miscarriage. 'Measles can also cause pneumonia, brain swelling, and death, with infants and immunocompromised individuals especially vulnerable to these risks,' Dr. Tran said in a separate statement. 'The safest and most effective way to protect yourself from measles is through immunization.' The United States has reported 1,088 cases this year, as of June 1, according to a Reuters report. Two children have died in the Texas outbreak. The Government of Canada's latest report shows there are 2,755 measles cases in nine jurisdictions, as of May 24, 2025. That's an increase of 244 measles cases since the previous report. As of June 3, 2025, Ontario has reported a total of 2,009 measles cases in 19 public health units, an increase of 121 cases since the previous week. The weekly provincial report indicates 74.9 percent of measles case in Ontario were infants, children and adolescents, while 24.5 percent were adults. More than 96 percent of all infant, child and adolescent outbreak cases were unimmunized, while 67.3 of adults were unimmunized. A total of 1.9 percent of all cases were pregnant women, with 74.4 percent unimmunized. Six cases of congenital measles, infants diagnosed in the first 10 days of life, have been identified since the Ontario outbreak began on October 30, 2024. SWPH reported 727 cases in the region from Oct 30, 2024 to June 5, 2025, 10 more measles cases since May 29, 2025. More than 74 percent of cases are 18 years old or younger. Nearly 89 percent of cases were unimmunized people. According to the World Health Organization (WHO), before widespread measles vaccinations were available in 1963, major epidemics occurred about every two-to-three years, causing an estimated 2.6 million deaths each year. An estimated 107,500 people died from measles in 2023. Accelerated immunization activities prevented an estimated 60 million deaths from 2000 to 2023, according to WHO. Vaccinations decreased estimated measles deaths from 800,062 in 2000 to 107,500 in 2022. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
